Dianthus Therapeutics (DNTH) Current Assets (2017 - 2025)

Dianthus Therapeutics' Current Assets history runs 9 years deep, the most recent figure standing at $409.4 million for Q4 2025.

• In Q4 2025, Current Assets rose 45.76% year-over-year to $409.4 million; the TTM figure through Dec 2025 stood at $409.4 million (up 45.76% YoY), while the FY2025 annual figure was $409.4 million, up 45.76% from the prior year.
• Current Assets was $409.4 million for Q4 2025 at Dianthus Therapeutics, down from $413.8 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $413.8 million in Q3 2025 to a low of $78.6 million in Q2 2023.
• Historically, Current Assets has averaged $222.1 million across 5 years, with a median of $194.0 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Current Assets sank 54.6% in 2022, then jumped 365.03% in 2024.
• A 5-year view of Current Assets shows it stood at $180.7 million in 2021, then tumbled by 54.6% to $82.0 million in 2022, then jumped by 116.32% to $177.5 million in 2023, then soared by 58.3% to $280.9 million in 2024, then jumped by 45.76% to $409.4 million in 2025.
• The last three Current Assets figures came in at $409.4 million (Q4 2025), $413.8 million (Q3 2025), and $263.6 million (Q2 2025), per Business Quant data.